Liquidia (NASDAQ:LQDA) Price Target Raised to $51.00

Liquidia (NASDAQ:LQDA) had its price target hoisted by Wells Fargo & Company from $44.00 to $51.00 in a research note published on Monday,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also recently issued reports on LQDA. Oppenheimer boosted their price objective on shares of Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research report on Thursday, March 12th. HC Wainwright raised their target price on shares of Liquidia from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. BTIG Research lifted their price target on shares of Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Lifesci Capital upgraded Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Finally, Jefferies Financial Group increased their price objective on Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, January 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Liquidia presently has an average rating of “Moderate Buy” and an average price target of $43.44.

Liquidia Stock Performance

LQDA stock opened at $36.61 on Monday. Liquidia has a twelve month low of $11.26 and a twelve month high of $46.67. The firm has a market cap of $3.23 billion, a price-to-earnings ratio of -44.11 and a beta of 0.52. The business’s fifty day simple moving average is $37.74 and its two-hundred day simple moving average is $31.73. The company has a quick ratio of 1.84, a current ratio of 2.01 and a debt-to-equity ratio of 2.97.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The firm had revenue of $92.02 million during the quarter, compared to analyst estimates of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The firm’s quarterly revenue was up 3072.4% compared to the same quarter last year. Analysts predict that Liquidia will post -1.51 earnings per share for the current year.

Insider Activity at Liquidia

In other news, CFO Michael Kaseta sold 36,932 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,382,364.76. Following the completion of the sale, the chief financial officer owned 350,919 shares of the company’s stock, valued at approximately $13,134,898.17. This represents a 9.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajeev Saggar sold 21,142 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $791,345.06. Following the transaction, the insider owned 176,883 shares in the company, valued at approximately $6,620,730.69. This represents a 10.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 230,848 shares of company stock worth $8,638,491 over the last quarter. Corporate insiders own 26.50% of the company’s stock.

Hedge Funds Weigh In On Liquidia

A number of large investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. purchased a new stake in Liquidia during the fourth quarter worth $25,000. NewEdge Advisors LLC purchased a new position in shares of Liquidia in the 2nd quarter valued at $25,000. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Liquidia in the 3rd quarter worth $30,000. FNY Investment Advisers LLC bought a new position in shares of Liquidia in the 3rd quarter worth $34,000. Finally, Covestor Ltd lifted its stake in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).